International Journal of Clinical Pharmacy

, Volume 39, Issue 1, pp 52–60 | Cite as

Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy

  • Elza Aparecida Machado DominguesEmail author
  • Mónica Ferrit-Martín
  • Miguel Ángel Calleja-Hernández
Research Article


Background Advances in the treatment of HIV infection have enabled better control of the disease, allowing patients to enjoy a longer life expectancy. However, the ageing of patients leads to an increased prevalence of cardiovascular disease. Various studies have found that pharmaceutical care results in better control of cardiovascular risk factors. Objective To measure the impact of pharmaceutical care on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy. Setting Outpatient pharmacy service of a tertiary hospital, Spain. Methods A pre/post-intervention quasi-experimental clinical study was conducted in which health education and pharmacist interventions to reduce cardiovascular risk factors were carried out in a single patient cohort using the Dader method of pharmacotherapy, with a 12-month follow-up period per patient. Patients included were older than 50 years, with moderate/elevated cardiovascular risk. Data were obtained from patient clinical histories, dispensing records and patient interviews, and were subjected to statistical analysis. Main outcome measure Cardiovascular risk estimated by SCORE and REGICOR equations. Results Forty-two patients completed the study. Of these, 93 % were men, with an average age of 57 years and 15 years since diagnosis of HIV. A reduction was observed in the mean values (baseline vs. 12 months) of the following cardiovascular risk factors: systolic blood pressure (P = 0.009), diastolic blood pressure (P = 0.010), total cholesterol (P = 0.006), low-density lipoprotein cholesterol (LDL-c; P = 0.039), triglycerides (P = 0.010) and total cholesterol/high-density lipoprotein cholesterol (HDL-c; P < 0.001). An increase in HDL-c (P = 0.037) was also observed. The average cardiovascular risk estimated by the SCORE instrument was reduced from 7.6 % at the beginning of the study to 6.4 % after 12 months (P = 0.039). The risk estimate according to REGICOR also decreased (P = 0.002). Over the 12-month period, 6.3 ± 3.4 interventions were carried out per patient. Quantitative ineffectiveness was the most prevalent negative outcome associated with medication throughout the study, and noncompliance was the most frequent cause. Interventions on health education were the most common, followed by interventions on improving adherence. Conclusion Pharmaceutical care, delivered as a combination of health education and pharmacotherapy follow-up to outpatients at a tertiary hospital, had a positive impact on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy.


HIV Older patients Pharmaceutical care Pharmacotherapy follow-up Spain 



This article is part of the doctoral thesis of Elza Domingues within the Doctoral Programme in Clinical Medicine and Public Health, Granada University, Spain. We acknowledge support from the Coordination for the Improvement of Higher Education Personnel (CAPES) Foundation, Brazil; the staff of the Virgen de las Nieves University Hospital, Spain; and Manuela Expósito Ruiz, FIBAO (Biohealth Research Foundation of Eastern Andalusia), Spain, for statistical analysis.


Research presented here was supported by funding from the CAPES Foundation, Brazil, process no. 0675/13-0.

Conflicts of interest

The authors declare that they have no conflict of interest.

Supplementary material

11096_2016_387_MOESM1_ESM.docx (25 kb)
Supplementary material 1 (DOCX 24 kb)


  1. 1.
    Morillo Verdugo R, Illaro Uranga A, Margusino Framinan L. Representación del grupo de trabajo de Atención Farmacéutica al paciente VIH de la SEFH. [Towards a new model of health care delivery in pharmaceutical care to the HIV + patient]. Farm Hosp. 2013;37(1):1–3 (Spanish).PubMedGoogle Scholar
  2. 2.
    United Nations Programme on HIV/AIDS. HIV and aging: a special supplement to the UNAIDS report on the global AIDS epidemic 2013 (2013). Accessed 10 June 2016.
  3. 3.
    Diez M, Diaz A, Garriga C, Pons M, Ten A, Marcos H, et al. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. Euro Surveill. 2014; 19(20). doi: 10.2807/1560-7917.ES2014.19.20.20805.
  4. 4.
    Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sghem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398. Accessed 10 June 2016.
  6. 6.
    Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.CrossRefPubMedGoogle Scholar
  8. 8.
    Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Sabater Hernandez D, Silva Castro MM, Faus Dader MJ. Dader method. Medication review with follow-up guidelines. 3rd ed. Granada: Pharmaceutical Care Research Group; 2007 (Spanish).Google Scholar
  10. 10.
    Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253–61 (Spanish).CrossRefPubMedGoogle Scholar
  11. 11.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract. 2010;64(9):1252–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Masiá M, Pérez-Cachafeiro S, Leyes M, López-Aldeguer J, López M, Segura F, et al. Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011. Enferm Infecc Microbiol Clin. 2012;30(9):517–27 (Spanish).CrossRefPubMedGoogle Scholar
  15. 15.
    Estrada V, Bernardino JI, Masiá M, Iribarren JA, Ortega A, Lozano F, et al. Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. HIV Clin Trials. 2015;16(2):57–65.CrossRefPubMedGoogle Scholar
  16. 16.
    Marques LA, Galduróz JC, Fernandes MR, Oliveira CC, Beijo LA, Noto AR. Assessment of the effectiveness of pharmacotherapy follow-up in patients treated for depression. J Manag Care Pharm. 2013;19(3):218–27.PubMedGoogle Scholar
  17. 17.
    Firmino PYM, Vasconcelos TO, Ferreira CC, Moreira LM, Romero NR, Dias LA, et al. Cardiovascular risk rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical care. Braz J Pharm Sci. 2015;51(3):617–27.CrossRefGoogle Scholar
  18. 18.
    Ocampo CC, Garcia-Cardenas V, Martinez-Martinez F, Benrimoj SI, Amariles P, Gastelurrutia MA. Implementation of medication review with follow-up in a Spanish community pharmacy and its achieved outcomes. Int J Clin Pharm. 2015;37(5):931–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Torres-Degayón V, Torres-Murillo JM, Baena-Parejo MI, Muñoz-Villanueva MC, Montes-Redondo G, Calleja-Hernández MA, et al. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department. J Clin Pharm Ther. 2015;40(4):452–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Castaneda S, Melendez-Lopez S, Garcia E, De la Cruz H, Sanchez-Palacio J. The role of the pharmacist in the treatment of patients with infantile hemangioma using propranolol. Adv Ther. 2016;. doi: 10.1007/s12325-016-0391-9 (Forthcoming).PubMedPubMedCentralGoogle Scholar
  21. 21.
    Jódar-Sánchez F, Martín JJ, López del Amo MP, García L, Araújo-Santos JM, Epstein D. Cost-utility analysis of a pharmacotherapy follow-up for elderly nursing home residents in Spain. J Am Geriatr Soc. 2014;62(7):1272–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Jódar-Sánchez F, Malet-Larrea A, Martín JJ, García-Mochón L, López Del Amo MP, Martínez-Martínez F, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33(6):599–610.CrossRefPubMedGoogle Scholar
  23. 23.
    Amariles P, Sabater-Hernández D, García-Jiménez E, Rodriguez-Chamorro MA, Prats-Más R, Marin-Magán F, et al. Effectiveness of Dader Method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial. J Manag Care Pharm. 2012;18(4):311–23.PubMedGoogle Scholar
  24. 24.
    Neto PR, Marusic S, de Lyra Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharm Sci. 2011;14(2):249–63.CrossRefPubMedGoogle Scholar
  25. 25.
    Monroe AK, Rowe TL, Moore RD, Chander G. Medication adherence in HIV-positive patients with diabetes or hypertension: a focus group study. BMC Health Serv Res. 2013;13:488.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cioe PA, Crawford SL, Stein MD. Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults. J Assoc Nurses AIDS Care. 2014;25(1):60–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Federal University of Mato Grosso do SulCampo GrandeBrazil
  2. 2.Doctoral Programme in Clinical Medicine and Public HealthGranada UniversityGranadaSpain
  3. 3.Pharmacy Clinical Management DepartmentVirgen de las Nieves University HospitalGranadaSpain

Personalised recommendations